to Content
Header Image

Dr. Andrea RAPPAGLIOSI VP Health Policy & Government Relations Europe, Merck Serono International S. A.; Member, Economic and Social Policy Committee, EFPIA, Geneva


 Dr. Andrea Rappagliosi received a law degree from the University of Rome "La Sapienza" and completed a post-graduate Masters at the Istituto Superiore die Studi Legislativi (ISLE) from which he obtained a "Legislative Consultant Diploma". He began his career in the early eighties, first in the Italian Government as a member of staff for the State Undersecretary of the Treasury, then for the Italian Senate focused on drafting of legislative texts, comparative legal studies and public budget analysis.
 In 1992, he moved into healthcare and worked for The Ares-Serono Group as Head of the Institutional Affairs Department in charge of the Rome and Brussels offices and from 1995 to 1999, he was Public Affairs Director at Baxter Healthcare, part of the European Public Affairs team. He returned to Serono International, today Merck Serono International, as Vice President Corporate Health Policy & Government Relations.


- Member, European Commission High Level Pharmaceutical Forum / European Medicines Agency (EMEA) Committee for Orphan Medicinal Products Working Group with Interested Parties (COMP/WGIP) / HTAi Society Policy Forum / EFPIA Economic and Social Policy Committee / INTERPHARMA Economic and Policy Issues Committee / Editorial Board of the Journal of Commercial Biotechnology / British Institute of International and Comparative Law
- Vice Chairman, EUROPABIO, Board of Management
- Chair, EUROPABIO Healthcare Council
- Board, European Platform for Patients Organizations, Science & Industry (EPPOSI)


Patient Access to Innovation: Biopharmaceutical, 4th hurdles and socioeconomic issues  Journal of Commercial Biotechnology  Vol.7-4, 1-10, Henry Stewart Publications (2001).
Patient Access to Orphan drugs in the European Union  Pharmaceutical Policy and Law  Vol.3-2001-IOS Press
Parlamento :  The Government and State Shareholding: prospects and possible solutions for restructuring the Institutional system and reforming the bicameral Commission for State Shareholding April 1992
The European Files:  EU Orphan Drug Policy: a model for a global approach to rare diseases? December 2002 and  Biotechnology in healthcare: an EU crossroad between science & public health December 2005
EU Biopharmaceutical Review:  The role of biotech in promoting public health Winter 2004
Journal of Commercial Biotech:  Biotech in the European Union October 2004
Articles published on various economic and Institutional issues selected by the Review Selection Centre of the Chamber of Deputies and the Juridical Review Archive of the Juridical Documentation Institute of the CNR (National Council for Scientific Research)